Form S-3 Corbus Pharmaceuticals

Go back to Form S-3 Corbus Pharmaceuticals

Corbus Pharma (CRBP) Tops Q3 EPS by 2c

November 11, 2015 7:33 AM EST

Corbus Pharma (NASDAQ: CRBP) reported Q3 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).

Expected Near-Term Milestones

Continue to screen and enroll patients in both the Phase 2 studies in CF and in systemic sclerosis to remain on track... More

Corbus Pharma (CRBP) Files $100M Mixed Shelf

November 11, 2015 6:51 AM EST

Corbus Pharma (NASDAQ: CRBP) filed a registration with the U.S. SEC to sell up to $100 million of mixed securities.

... More